Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials ...
Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated ...
From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally ...
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback